The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma

https://doi.org/10.1016/0091-6749(93)90320-FGet rights and content

Abstract

Background: Allergen challenge of subjects with asthma produces an early asthmatic response, late asthmatic response, and increases bronchial responsiveness. Histamine partly mediates the early asthmatic response, and may play a role in late-phase responses. Azelastine has antiallergic properties and has been proposed as a treatment for asthma. We therefore investigated the contribution of histamine to late-phase responses with the use of the potent H1-receptor antagonist azelastine.

Methods: Ten subjects with atopic asthma were studied in a double-blind, randomized, placebo-controlled trial. Azelastine was administered over 4 days before allergen challenge. Changes in airway caliber were followed with measurements of forced expiratory volume in 1 second, and changes in bronchial responsiveness were followed by methacholine and prostaglandin D2 bronchial provocation tests.

Results: Azelastine significantly inhibited the development of the early asthmatic response. Azelastine had no effect on the late asthmatic response or on the development of allergen-induced increases in bronchial responsiveness. The power of the study was sufficient to have had a high probability of detecting any important differences between placebo and azelastine during the late phase.

Conclusions: Azelastine had no significant effect on the late-phase response model of asthma. This study does not support the hypothesis that histamine is an important mediator of the late asthmatic response or allergen-induced increases in bronchial responsiveness.

References (48)

  • S Ollier et al.

    The effect of single and multiple dose therapy with azelastine on the immediate asthmatic response to allergen provocation testing

    J Allergy Clin Immunol

    (1986)
  • JM Weiler et al.

    Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis

    J Allergy Clin Immunol

    (1988)
  • JP Kemp et al.

    A dose-response study of the bronchodilator action of azelastine in asthma

    J Allergy Clin Immunol

    (1987)
  • H Chai et al.

    Standardization of bronchial inhalation challenge procedures

    J Allergy Clin Immunol

    (1975)
  • WW Busse et al.

    The relationship between plasma histamine concentrations and bronchial obstruction to antigen challenge in allergic rhinitis

    J Allergy Clin Immunol

    (1989)
  • P Rafferty et al.

    The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma

    J Allergy Clin Immunol

    (1989)
  • SR Durham et al.

    Immunologic studies in allergen-induced late phase asthmatic reactions

    J Allergy Clin Immunol

    (1984)
  • PH Howarth et al.

    The relationship between mast cell mediator release and bronchial reactivity in allergic asthma

    J Allergy Clin Immunol

    (1987)
  • T Nakazawa et al.

    Inhibitory effects of various drugs on dual asthmatic responses in wheat flour-sensitive subjects

    J Allergy Clin Immunol

    (1976)
  • GI Town et al.

    Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine and allergen in subjects with asthma

    J Allergy Clin Immunol

    (1990)
  • ST Holgate et al.

    Astemizole and other H1-antihistaminic drug treatment of asthma

    J Allergy Clin Immunol

    (1985)
  • DW Cockcroft et al.

    Allergen-induced increase in non-allergic bronchial reactivity

    Clin Allergy

    (1977)
  • JGR De Monchy et al.

    Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions

    Am Rev Respir Dis

    (1985)
  • PM O'Byrne et al.

    Late asthmatic responses

    Am Rev Respir Dis

    (1987)
  • Cited by (26)

    • Mechanisms of airway hyperresponsiveness

      2006, Journal of Allergy and Clinical Immunology
      Citation Excerpt :

      Both desloratadine and fexofenadine have been shown to inhibit allergen-induced inflammation and airway hyperresponsiveness in mice,82-84 and this may result from the inhibition of TH2 CD4+-cell recruitment shown in H1 receptor knockout mice. However, H1 blockers have historically been ineffective in blocking allergen-induced LAR in human beings.85 Despite the numerous studies related to the mechanism of allergen-induced airway inflammation and the clear association with allergen-induced AHR, the precise mechanisms linking airway inflammation to the transient associated AHR remain elusive.86

    View all citing articles on Scopus

    Supported in part by a programme grant from the British Medical Research Council.

    View full text